SHANGHAI, China and PRINCETON, N.J., May 12, 2026
Hengrui Pharma and Bristol Myers Squibb (BMS) have announced a landmark global strategic collaboration and licensing agreement focused on advancing a broad portfolio of innovative therapies across oncology, hematology, and immunology, in a deal valued at up to $15.2 billion. The partnership combines 13 early-stage therapeutic programs and reflects one of the largest recent multinational biopharma collaborations aimed at accelerating next-generation drug discovery and development for serious diseases with significant unmet medical need. The strategic alliance strengthens both companies’ long-term innovation pipelines while expanding cross-border pharmaceutical collaboration between the United States and China.
The agreement includes four oncology and hematology programs originating from Hengrui Pharma, four immunology assets from Bristol Myers Squibb, and five jointly developed discovery-stage programs leveraging Hengrui’s platform technologies and research capabilities. Company executives stated that the collaboration is designed to combine BMS’s global clinical development, regulatory, and commercialization expertise with Hengrui’s rapidly growing innovation engine and efficient early-stage drug development infrastructure.
Strategic Collaboration Expands Global Drug Development
Under the terms of the agreement, Bristol Myers Squibb will receive exclusive worldwide rights to Hengrui-originated assets outside mainland China, Hong Kong SAR, and Macau SAR, while Hengrui Pharma will obtain exclusive rights to BMS-originated immunology assets within those territories. Hengrui will also play a major role in early clinical development activities intended to accelerate proof-of-concept studies and streamline advancement of the pipeline into later-stage clinical evaluation.
The financial structure of the collaboration highlights the scale and strategic significance of the transaction. Bristol Myers Squibb will pay Hengrui up to $950 million upfront and near-term payments, including an immediate $600 million payment and additional anniversary payments tied to collaboration milestones. The total potential value of the partnership could reach approximately $15.2 billion, including development, regulatory, commercial, and option-related milestone payments, alongside tiered royalties on future product sales outside the Hengrui territory.
Advertisement
Industry analysts believe the collaboration represents a major validation of Hengrui Pharma’s expanding global research capabilities and demonstrates increasing interest among multinational pharmaceutical companies in accessing innovative drug discovery platforms emerging from China’s biotechnology sector.
Oncology and Immunology Remain Major Innovation Focus
The alliance primarily targets therapeutic areas experiencing intense global research activity, including cancer, hematologic diseases, and chronic immune-mediated disorders. Pharmaceutical companies worldwide continue investing heavily in oncology and immunology due to rising disease prevalence, strong market demand for targeted therapies, and advances in precision medicine technologies.
BMS executives stated that the collaboration aligns with the company’s long-term strategy to strengthen portfolio growth while maintaining disciplined capital allocation and innovation-focused partnerships. By combining complementary scientific expertise across geographies, the companies aim to accelerate early clinical learning and identify high-value therapeutic candidates capable of addressing major unmet patient needs.
Hengrui Pharma leadership also emphasized that the partnership reflects the company’s continued effort to expand internationally and strengthen its position as a global biopharmaceutical innovator. The company has increasingly focused on developing advanced platform technologies and differentiated therapeutic programs across oncology, immunology, cardiovascular disease, neuroscience, and metabolic disorders.
Cross-Border Biopharma Partnerships Continue Growing
The transaction further highlights the growing importance of international pharmaceutical collaborations in accelerating innovation and reducing development timelines for complex therapeutic programs. As competition intensifies across the global biotechnology industry, strategic licensing agreements and co-development partnerships are increasingly becoming central components of long-term pipeline expansion strategies.
Analysts believe large-scale alliances such as the BMS-Hengrui collaboration may become more common as pharmaceutical companies seek access to novel platform technologies, regional clinical development expertise, and diversified innovation pipelines. The agreement remains subject to customary regulatory review processes, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act, with closing expected during the third quarter of 2026.
The collaboration positions both companies to accelerate development of multiple innovative therapies while reinforcing the growing role of global scientific partnerships in shaping the future of oncology, hematology, and immunology drug development.
Source: Bristol Myers Squibb, Hengrui Pharma press release
